TY - JOUR
T1 - Modeling rotavirus infection and antiviral therapy using primary intestinal organoids
AU - Yin, Yuebang
AU - Bijvelds, Marcel
AU - Dang, Wen
AU - Xu, Lei
AU - Van Der Eijk, Annemiek A.
AU - Knipping, Karen
AU - Tuysuz, Nesrin
AU - Dekkers, Johanna F.
AU - Wang, Yijin
AU - De Jonge, Jeroen
AU - Sprengers, Dave
AU - Van Der Laan, Luc J.W.
AU - Beekman, Jeffrey M.
AU - Ten Berge, Derk
AU - Metselaar, Herold J.
AU - De Jonge, Hugo
AU - Koopmans, Marion P.G.
AU - Peppelenbosch, Maikel P.
AU - Pan, Qiuwei
N1 - Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Despite the introduction of oral vaccines, rotavirus still kills over 450,000 children under five years of age annually. The absence of specific treatment prompts research aiming at further understanding of pathogenesis and the development of effective antiviral therapy, which in turn requires advanced experimental models. Given the intrinsic limitations of the classical rotavirus models using immortalized cell lines infected with laboratory-adapted strains in two dimensional cultures, our study aimed to model infection and antiviral therapy of both experimental and patient-derived rotavirus strains using three dimensional cultures of primary intestinal organoids. Intestinal epithelial organoids were successfully cultured from mouse or human gut tissues. These organoids recapitulate essential features of the in vivo tissue architecture, and are susceptible to rotavirus. Human organoids are more permissive to rotavirus infection, displaying an over 10,000-fold increase in genomic RNA following 24 h of viral replication. Furthermore, infected organoids are capable of producing infectious rotavirus particles. Treatment of interferon-alpha or ribavirin inhibited viral replication in organoids of both species. Importantly, human organoids efficiently support the infection of patient-derived rotavirus strains and can be potentially harnessed for personalized evaluation of the efficacy of antiviral medications. Therefore, organoids provide a robust model system for studying rotavirus-host interactions and assessing antiviral medications.
AB - Despite the introduction of oral vaccines, rotavirus still kills over 450,000 children under five years of age annually. The absence of specific treatment prompts research aiming at further understanding of pathogenesis and the development of effective antiviral therapy, which in turn requires advanced experimental models. Given the intrinsic limitations of the classical rotavirus models using immortalized cell lines infected with laboratory-adapted strains in two dimensional cultures, our study aimed to model infection and antiviral therapy of both experimental and patient-derived rotavirus strains using three dimensional cultures of primary intestinal organoids. Intestinal epithelial organoids were successfully cultured from mouse or human gut tissues. These organoids recapitulate essential features of the in vivo tissue architecture, and are susceptible to rotavirus. Human organoids are more permissive to rotavirus infection, displaying an over 10,000-fold increase in genomic RNA following 24 h of viral replication. Furthermore, infected organoids are capable of producing infectious rotavirus particles. Treatment of interferon-alpha or ribavirin inhibited viral replication in organoids of both species. Importantly, human organoids efficiently support the infection of patient-derived rotavirus strains and can be potentially harnessed for personalized evaluation of the efficacy of antiviral medications. Therefore, organoids provide a robust model system for studying rotavirus-host interactions and assessing antiviral medications.
KW - Interferon
KW - Intestinal organoids
KW - Ribavirin
KW - Rotavirus
UR - http://www.scopus.com/inward/record.url?scp=84942784008&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2015.09.010
DO - 10.1016/j.antiviral.2015.09.010
M3 - Article
C2 - 26408355
AN - SCOPUS:84942784008
SN - 0166-3542
VL - 123
SP - 120
EP - 131
JO - Antiviral Research
JF - Antiviral Research
ER -